Enrolling MASH - Metabolic Dysfunction-Associated Steatohepatitis Drug: HU6 Other: Placebo EASi-PROTKT - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease
Researchers frequently examine how DSIP interacts with central nervous system signaling networks involved in slow-wave sleep and sleep architecture
Your provider will discuss whether to continue, adjust, or discontinue semaglutide based on individual circumstances
Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for type 2 diabetes, have shown promise in managing GDM by improving glycemic control, enhancing insulin sensitivity, and assisting in weight management
Sodium and Calcium Balance : Imbalances in sodium and calcium levels can also lead to muscle pain and discomfort
GLP-1 RAs were administered at higher doses than earlier T2DM-focused RCTs to optimize weight loss, leading to mean reductions ranging from 5.3 to 21.2 kg
